Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

PuraPly™ Antimicrobial Wound Matrix and Wound Management

NCT03070938 · View on ClinicalTrials.gov ↗

Study Summary

The PuraPly Antimicrobial Wound Matrix (PuraPly AM) case series is a prospective, observational study for patients who have received PuraPly AM which consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) and is intended for the management of wounds; no experimental intervention is involved.

Interventions

  • DEVICE PuraPly™ Antimicrobial Wound Matrix

Study Locations (1)

New York

  • Winthrop University Hospital — Mineola

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2016-11
Est. Completion 2017-10

Sponsor

Organogenesis

7 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03070938

The ClinicalTrials.gov registry entry for NCT03070938 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organogenesis, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Surgical Wound appearing as the primary indexed condition, and to 1 intervention — of which PuraPly™ Antimicrobial Wound Matrix is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03070938 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03070938 about?

NCT03070938 is a clinical study titled "PuraPly™ Antimicrobial Wound Matrix and Wound Management". The PuraPly Antimicrobial Wound Matrix (PuraPly AM) case series is a prospective, observational study for patients who have received PuraPly AM which consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) and is intended for the management of wounds; no experimental ...

What is the current status of trial NCT03070938?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2016-11. Estimated completion is 2017-10.

What conditions does trial NCT03070938 study?

This clinical trial studies the following conditions: Surgical Wound, Venous Ulcer, Pressure Ulcer, Trauma Wound, Diabetic Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03070938?

The interventions under investigation include: PuraPly™ Antimicrobial Wound Matrix (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03070938?

This trial is sponsored by Organogenesis, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03070938 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial